The phase 2 diabetes trial is distinct from the retatrutide obesity trial and from later phase 3 research. Its active comparator and placebo comparisons answer different questions. Primary trial
Study snapshot
The double-blind phase 2 study randomized 281 adults with type 2 diabetes across placebo, dulaglutide, and several retatrutide groups. HbA1c change at 24 weeks was primary; later HbA1c and weight outcomes were secondary. Most retatrutide groups exceeded placebo for HbA1c reduction, but not every group exceeded the active comparator. The efficacy analysis included 275 participants. Gastrointestinal adverse events were common, and Eli Lilly funded the study. Registration: NCT04867785. Primary trial
Our appraisal: preserve the comparison matrix
With several active groups and two comparators, a single “successful trial” label conceals useful information. Each result needs the active group, comparator, endpoint, and assessment time. A favorable placebo comparison cannot automatically become superiority over the active comparator.
In an invented example, treatment A could outperform placebo while being indistinguishable from treatment B within the available precision. Those are compatible findings. Reporting only the favorable contrast would leave the reader with an incomplete comparison.
Population and timing checks
The randomized, safety, efficacy, and completed-treatment populations should be extracted separately. Differences in counts require the report's stated explanations, not assumptions that all missing participants had the same outcome.
Our full-paper review should also examine escalation-group definitions, prespecified comparisons, multiplicity, estimands, and handling of missing measurements. A 24-week glycemic result and a 36-week weight result should not appear in a table with one unlabeled time column.
This page appraises a historical trial. It does not equate a catalog shorthand with the trial's material, establish current regulatory status, or offer a regimen.
What controlled studies contribute
In the phase 2 diabetes trial, gastrointestinal adverse events were reported in 67 of 190 retatrutide participants, six of 45 placebo participants and 16 of 46 dulaglutide participants. These are participants with events, not the number of separate episodes. The retatrutide figure combines groups with different results, so it should not be presented as a uniform probability for every study exposure or every person.
That diabetes trial reported no severe hypoglycemia and no deaths during the study. Those observations are useful, but the study was too limited to prove either outcome impossible. “None observed” is a statement about the monitored sample and follow-up, not a guarantee.
Frequently asked questions
Was this the phase 2 obesity trial?
No. This study enrolled people with type 2 diabetes.
Was placebo the only comparator?
No. Dulaglutide was also included.
Did all active groups have identical comparative findings?
No. The comparator and group must be specified.
Was weight the primary endpoint?
No. The primary endpoint was HbA1c change at 24 weeks.
Can 281 and 275 be used interchangeably?
No. They describe different analysis populations in the report.
Does this provide an individual treatment plan?
No. It is research interpretation, not prescribing guidance.
What remains before release?
Full analysis-plan, participant-flow, safety, publication-history, and related-page overlap checks.